Edition:
United States

Cidara Therapeutics Inc (CDTX.OQ)

CDTX.OQ on NASDAQ Stock Exchange Global Market

5.95USD
4:00pm EDT
Change (% chg)

$0.52 (+9.68%)
Prev Close
$5.43
Open
$5.75
Day's High
$6.05
Day's Low
$5.50
Volume
87,017
Avg. Vol
40,015
52-wk High
$8.80
52-wk Low
$3.72

Chart for

About

Cidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections. Its product portfolio... (more)

Overall

Beta: --
Market Cap(Mil.): $116.05
Shares Outstanding(Mil.): 21.39
Dividend: --
Yield (%): --

Financials

  CDTX.OQ Industry Sector
P/E (TTM): -- 243.17 32.94
EPS (TTM): -3.21 -- --
ROI: -81.71 -7.30 12.79
ROE: -93.11 -10.05 14.67

BRIEF-Cidara Announces Stock And Warrants Offering Worth $120 Mln

* CIDARA THERAPEUTICS ANNOUNCES OFFERING OF COMMON STOCK AND WARRANTS

May 21 2018

BRIEF-Cidara Therapeutics Files For Stock Shelf Of Up To $10 Mln

* CIDARA THERAPEUTICS INC FILES FOR STOCK SHELF OF UP TO $10 MILLION – SEC FILING Source text (https://bit.ly/2kebUqL) Further company coverage:

May 21 2018

BRIEF-Cidara Reports Q1 Loss Per Share $0.80

* CIDARA PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 10 2018

BRIEF-Cidara Says Additional Data Confirm Positive Results In Antifungal Rezafungin

* CIDARA THERAPEUTICS PROVIDES CLINICAL DATA UPDATES FOR ITS LEAD ANTIFUNGAL REZAFUNGIN

Mar 21 2018

BRIEF-Cidara Reports Positive Topline Results From Phase 2 Strive Trial Of Lead Antifungal Rezafungin

* CIDARA THERAPEUTICS REPORTS POSITIVE TOPLINE RESULTS FROM PHASE 2 STRIVE TRIAL OF LEAD ANTIFUNGAL REZAFUNGIN

Mar 19 2018

BRIEF-Cidara Posts Q4 Loss Per Share $0.69​

* CIDARA PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Feb 27 2018

BRIEF-Cidara Therapeutics Completes Enrollment in Phase 2 Strive Trial for Antifungal Rezafungin

* CIDARA THERAPEUTICS COMPLETES ENROLLMENT IN PHASE 2 STRIVE TRIAL EVALUATING NOVEL ANTIFUNGAL REZAFUNGIN (CD101 IV) IN INVASIVE FUNGAL INFECTIONS Source text for Eikon: Further company coverage:

Nov 28 2017

Earnings vs. Estimates